Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12523941 | 1.00 | KMT2A (0.56) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL3563747 | 0.78 | KMT2A (0.63) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL3563749 | 0.78 | KMT2A (0.63) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL29768778 | 0.73 | KMT2A (1.00) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL1772824 | 0.73 | KMT2A (0.69) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL17875019 | 0.73 | KMT2A (0.69) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL28322044 | 0.73 | KMT2A (0.69) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL29768777 | 0.73 | KMT2A (1.00) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL257134 | 0.73 | KMT2A (1.00) | KMT2ACDC7AXLGPR84HASPIN | |
| SCHEMBL30165674 | 0.73 | KMT2A (0.69) | KMT2ACDC7AXLGPR84HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | KMT2A 721/4885CDC7 3658/4885AXL 1181/4885 |
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | REN, AGTR1, AGTR2 | KMT2A 721/4885CDC7 3658/4885AXL 1181/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | KMT2A 1998/4885CDC7 3435/4885AXL 1550/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | KMT2A 721/4885CDC7 3658/4885AXL 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.